Helicobacter pylori infection
Methodology & AI Transparency ⓘ
Helicobacter pylori infection Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Physicians managing Helicobacter pylori infection (A04.8; Bacterial, Viral & Fungal Infections) utilize bacterial/fungal culture with in Helicobacter pylori infection (A04.8: antimicrobial susceptibility testing) and objective Complete Blood Count in Helicobacter pylori infection (A04.8: (WBC & Differential)) targets (WBC 4.0 – 10.0 x10^3/uL (A04.8)) to prevent progression and functional morbidity.
- 2 Real-world patient consensus: Federal ICD-10-CM code A04.8 categorizes Helicobacter pylori infection under Bacterial, Viral & Fungal Infections.
- 3 Typical cash cost range: Clinicians assessing Helicobacter pylori infection focus on pathogen-associated molecular pattern in Helicobacter pylori infection (A04.8: (PAMP) innate immune) and targeted history.
- 4 Top reported side effects / signs: Longitudinal Helicobacter pylori infection monitoring tracks Complete Blood Count in Helicobacter pylori infection (A04.8: (WBC & Differential)) toward WBC 4.0 – 10.0 x10^3/uL (A04.8).
Ask our AI Specialists anything about Helicobacter pylori infection
What Is Helicobacter pylori infection?
Physicians managing Helicobacter pylori infection (A04.8; Bacterial, Viral & Fungal Infections) utilize bacterial/fungal culture with in Helicobacter pylori infection (A04.8: antimicrobial susceptibility testing) and objective Complete Blood Count in Helicobacter pylori infection (A04.8: (WBC & Differential)) targets (WBC 4.0 – 10.0 x10^3/uL (A04.8)) to prevent progression and functional morbidity.
Pathophysiology, Underlying Causes & Clinical Presentation
In Helicobacter pylori infection (A04.8), physiological disruption stems from pathogen-associated molecular pattern in Helicobacter pylori infection (A04.8: (PAMP) innate immune), informing Bacterial, Viral & Fungal Infections protocols that track C-Reactive Protein / in Helicobacter pylori infection (A04.8: Procalcitonin) (Resolution to baseline (A04.8)).
Common Symptoms & Clinical Signs
- • Presentation of Helicobacter pylori infection (A04.8): acute fever, chills, in Helicobacter pylori infection (A04.8: malaise, and myalgias)
- • Secondary Helicobacter pylori infection clinical sign: sore throat, productive in Helicobacter pylori infection (A04.8: cough, sinus/ear pain,)
- • Symptom flares in Helicobacter pylori infection correlating with Complete Blood Count in Helicobacter pylori infection (A04.8: (WBC & Differential)) deviation outside WBC 4.0 – 10.0 x10^3/uL (A04.8)
- • Functional infections & antivirals impact requiring bacterial/fungal culture with in Helicobacter pylori infection (A04.8: antimicrobial susceptibility testing) evaluation (A04.8)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Helicobacter pylori infection Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | A04.8 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Bacterial, Viral & Fungal Infections | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Complete Blood Count in Helicobacter pylori infection (A04.8: (WBC & Differential)) | WBC 4.0 – 10.0 x10^3/uL (A04.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: C-Reactive Protein / in Helicobacter pylori infection (A04.8: Procalcitonin) | Resolution to baseline (A04.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Targeted PCR / in Helicobacter pylori infection (A04.8: Culture & Sensitivity) | Pathogen clearance / negative test (A04.8) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Helicobacter pylori infection
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Idkit Hp One (Citric Acid Anhydrous and 13c Urea) Idkit Hp One • RxCUI RXN-B50402100 | Helicobacter pylori Diagnostic | 91% | $1.8700 | $ 143.14 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Helicobacter pylori infection)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the: What a 1,046-Participant Study Found Both vonoprazan-based regimens were superior to proton pump inhibitor-based triple therapy in clarithromycin-resistant strains and in the overall study population. Gastroenterology • 2022-09-15 • Phase III Randomized Trial | N = 1,046 | 96/100 | PMID 35679950 ↗ |
| New Insights on Vonoprazan-based quadruple therapy is non-inferior to esomeprazole-based: What a 510-Participant Study Found Vonoprazan was found to be well-tolerated and non-inferior to esomeprazole for eradicating H. Chinese medical journal • 2025-11-20 • Phase III Randomized Trial | N = 510 | 93/100 | PMID 39965795 ↗ |
| New Insights on Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and: What a 263-Participant Study Found Vonoprazan was well tolerated and non-inferior to lansoprazole for duodenal ulcer healing and achieved H. Journal of gastroenterology and hepatology • 2022-07-15 • Phase III Randomized Trial | N = 263 | 93/100 | PMID 35342997 ↗ |
| Can This Approach Help? Inside the Latest Research on Efficacy of keverprazan-based quadruple therapy for Helicobacter pylori Keverprazan 20 mg twice daily, used as a component of bismuth quadruple therapy, provided effective H. International journal of antimicrobial agents • 2024-11-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39293772 ↗ |
| Can This Approach Help? Inside the Latest Research on Sequential eradication of Helicobacter pylori as a treatment for immune Pylori eradication rate, but also a remarkable platelet response for ITP patients. Annals of hematology • 2022-07-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 35643952 ↗ |
Helicobacter pylori infection Patient Community & “People Like Me” Threads
Filter Helicobacter pylori infection community threads and patient logs by age, biological sex, dosage, and treatment duration.